The In Vitro Diagnostic Regulation (IVDR) is the European Union’s legal framework governing medical devices used for testing human samples like blood, urine, and tissue. It replaced the older In Vitro Diagnostic Directive (IVDD) to create stricter rules for safety, transparency, and clinical evidence. If you are a manufacturer, a laboratory, or a healthcare provider working with diagnostic tests, this regulation changes how those tests are approved and monitored in the EU.
What Is Ivdr Eu Regulation For Diagnostic Devices?
The IVDR is EU Regulation 2017/746. It sets the rules for placing in vitro diagnostic medical devices on the European market. These devices include pregnancy tests, blood glucose monitors, HIV tests, and cancer screening assays. The regulation took full effect on May 26, 2022, replacing the previous directive that had been in place since 1998.
The core change is a shift toward stricter oversight. Under the old IVDD, most tests were self-certified by the manufacturer with little outside review. Under the IVDR, a much larger share of devices requires review by an independent organization called a Notified Body before they can be sold.
Why Did the EU Replace the IVDD With the IVDR?
The IVDD was written in the late 1990s. At that time, diagnostic technology was simpler. The EU determined that the old system did not adequately address new risks, particularly for genetic testing and companion diagnostics that guide treatment decisions.
The IVDR responds to several documented failures. Some high-profile diagnostic tests performed poorly in practice, and the EU wanted a system that required clinical evidence before a product reached patients. The regulation also aims to improve transparency by creating a public database of all certified devices, including safety alerts and certificates.
Another driver was the lack of a unified approach across member states. Different countries applied the old directive in different ways, creating an uneven market. The IVDR is a regulation rather than a directive, meaning it applies identically in all EU countries without needing national implementation laws.
What Devices Are Covered Under the IVDR?
The IVDR covers any device intended for the examination of human specimens to provide information for diagnostic, monitoring, or compatibility purposes. This includes a wide range of products:
- Blood glucose monitors for diabetes management
- Pregnancy and fertility tests
- Infectious disease tests such as those for HIV, hepatitis, and COVID-19
- Genetic tests, including those for hereditary conditions
- Cancer screening and diagnostic assays
- Blood typing tests for transfusions and transplants
- Companion diagnostics that determine whether a specific drug is appropriate for a patient
Some products that were previously unregulated are now covered. These include certain genetic tests offered directly to consumers and some laboratory-developed tests, though the latter have special transition rules. The regulation also covers software used for diagnostic purposes, including algorithms that interpret test results.
How Does the IVDR Classify Diagnostic Devices by Risk?
The IVDR introduces a four-tier risk classification system for diagnostic devices. This is one of the most significant departures from the old directive. Devices are grouped into Class A, B, C, and D, with Class D representing the highest risk.
Class D includes tests for blood transfusion compatibility, infectious agents with high transmission risk, and certain blood-borne pathogens. Class C covers most other infectious disease tests, genetic tests, and tests used to screen for cancer. Class B includes most routine tests like pregnancy tests and basic hormone assays. Class A includes low-risk products like specimen collection containers and laboratory instruments.
Higher classification means more scrutiny. Class D devices require the most extensive clinical evidence and face the most frequent surveillance audits. Class A devices generally do not require Notified Body involvement unless they are sold sterile or have a measuring function.
What Clinical Evidence Does the IVDR Require?
The IVDR demands that manufacturers demonstrate their device performs as intended based on scientific validity, analytical performance, and clinical performance. Scientific validity means the analyte being measured is actually linked to the clinical condition in question. Analytical performance refers to how accurately the device measures that analyte. Clinical performance means the device correctly identifies or predicts the condition it is designed to detect.
Manufacturers must compile a Performance Evaluation Report that documents all three elements. For many devices, this requires new clinical studies. Under the old directive, most manufacturers could rely on literature reviews and historical data. The IVDR raises the bar by requiring studies conducted specifically on the device in question, unless the manufacturer can justify why existing data is sufficient.
Some research suggests the increased evidence burden has slowed device approvals. The transition period has been extended multiple times to give manufacturers and Notified Bodies more time to comply. As of the current transition schedule, some legacy devices can remain on the market under certain conditions, but the long-term expectation is full IVDR compliance for all devices.
What Does the IVDR Require of Laboratories and Healthcare Providers?
Laboratories that develop their own tests in-house, called laboratory-developed tests or in-house tests, face new requirements under the IVDR. If a laboratory develops a test for its own use, it must operate under a quality management system and meet specific safety and performance standards. The regulation states that such tests must be manufactured using a quality management system that complies with ISO 15189 or equivalent standards.
However, there are limits. The IVDR does not require Notified Body review for in-house tests, but it does require the laboratory to demonstrate that no equivalent commercially available device meets the patient’s needs. This is a significant change from previous practice, where in-house tests were largely unregulated.
Healthcare providers and purchasing departments must also verify that the devices they buy carry the CE mark under the IVDR. Devices certified under the old IVDD have a limited transition window. After that window closes, devices without proper IVDR certification cannot legally be sold in the EU.
What Are the Biggest Challenges With IVDR Implementation?
The most pressing challenge is capacity. Notified Bodies are the organizations that audit and certify high-risk devices. There were only a handful of Notified Bodies designated under the IVDR in its early years, and the workload has been enormous. This has created backlogs and delays for manufacturers seeking certification.
Smaller manufacturers face particular difficulty. The cost of compliance has risen substantially because of the need for more clinical data, more rigorous quality systems, and more detailed technical documentation. Some small companies have chosen to withdraw certain products from the EU market rather than bear the cost of certification.
Another challenge is the requirement for unique device identification, or UDI. Every device must carry a unique code that can be traced through the supply chain. This is designed to improve post-market surveillance and recall management, but it requires significant database infrastructure and labeling changes.
Frequently Asked Questions
When did the IVDR come into force?
The IVDR was published in May 2017 and became applicable on May 26, 2022. Transition periods for some legacy devices extend beyond that date.
Does the IVDR apply to laboratory-developed tests?
Yes, but with different requirements than commercial devices. In-house tests must meet quality management standards, but they do not require Notified Body review if no equivalent commercial device is available.
What is a Notified Body under the IVDR?
A Notified Body is an independent organization designated by an EU member state to assess whether medical devices meet regulatory requirements. Under the IVDR, Notified Bodies are required for most devices above Class A risk.
How does the IVDR differ from the old IVDD?
The IVDR requires more clinical evidence, introduces a formal risk classification system, expands the scope of regulated devices, and mandates a public database for device transparency. The old directive allowed most devices to be self-certified without independent review.
The IVDR represents a fundamental shift in how diagnostic devices are regulated in Europe. It raises the standard of evidence required before a test reaches patients, and it brings greater transparency to a market that previously operated with limited oversight. For manufacturers, the cost and complexity have increased. For patients and healthcare providers, the regulation aims to ensure that the diagnostic tests they rely on are backed by solid clinical evidence. The transition has been difficult, but the regulatory direction is clear: diagnostic devices must meet higher standards of proof, and that expectation is not going away.
